Skip to Content

Analysts at William Blair lower their earnings forecasts for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Analysts at William Blair lower their earnings forecasts for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Neurocrine Biosciences, Inc.’s NBIX Research analysts from William Blair decreased their projections for Neurocrine Biosciences’ earnings per share (EPS) for the fiscal year 2024 in a study that was made public on Tuesday, January 10, 2019. Minter, an analyst for William Blair, recently revised his earlier projection of the company’s earnings per share, bringing it down from $8.25 to $4.79. The current projection for Neurocrine Biosciences’ stock price for the year is $1.93 per share. Here’s a good example: William Blair projected that Neurocrine Biosciences would earn $9.82 per share for the fiscal year that will end in 2025.

Additionally, NBIX has obtained commentary from various other brokerages in the industry. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $138.00 to $143.00 and gave the stock an “overweight” rating in a research note published on Thursday, November 3. October 11 saw the publication of a research note by UBS Group, which resulted in the addition of neurocrine biosciences to the firm’s coverage universe. They gave the stock a “buy” rating and set a price objective of $136.00 for the shares of the company’s stock. Citigroup changed its rating on Neurocrine Biosciences from “hold” to “buy” in a research note published on Monday, October 24.

Additionally, they increased their price target for the company from $114.00 to $128.00. SVB Leerink increased their target price for Neurocrine Biosciences from $100.00 to $115.00 and categorized the company as “market perform” in a research report published on November 2. Last but not least, on November 2, Morgan Stanley published a research report that raised their price objective for Neurocrine Biosciences from $102.00 to $120.00 and rated the company as “equal weight.” This certainly does not make it the case that this is the least important item. Seven analysts have given the stock a hold rating, nine analysts have given the stock a buy rating, and one analyst has given the stock a strong buy rating. The information from Bloomberg indicates that the current recommendation for Neurocrine Biosciences is a “Moderate Buy” and that the price target has been established at $122.24.

NASDAQ: NBIX was first available for trading on Thursday with an opening price of $110.49. The company’s simple moving average over the past 50 days comes in at $119.77, and the simple moving average over the past 200 days comes in at $109.38. Given the company’s current market value, which is $10.62 billion, its P/E ratio, which is 193.85 percent, and its beta value, which is 0.54 percent, the company has adequate financial resources. Neurocrine Biosciences hit a low of $72.28 over the past year, while the company reached a high of $129.29 over the same period.

The quarterly financial results for Neurocrine Biosciences (NASDAQ: NBIX) were made public on Tuesday, November 1, 2018. The company had prepared these results in advance. The company reported earnings per share (EPS) for the period at $0.69, which is $0.15 lower than the average estimate of $0.84. In reality, the company brought in $387.90 million in revenue during the quarter, which is significantly higher than the $378.05 million projected to bring in during the period in question. The 4.06% return on equity and the 4.19% net margin at Neurocrine Biosciences demonstrate the company’s successful performance.

Recently, several institutional investors and hedge funds have either increased the amount of NBIX they are holding in their portfolios or decreased the amount of NBIX they are holding. During the first three months of the year, Acadian Asset Management LLC spent $27,000 to acquire shares of Neurocrine Biosciences. These shares were purchased through an outright purchase. The value of Covestor Ltd.’s holdings in Neurocrine Biosciences increased by 431.0% during the first three months of the year. After making additional purchases totaling 306 shares over the most recent fiscal quarter, Covestor Ltd. now holds 377 shares of the company’s stock, which have a combined value of $35,000. During the third quarter of the fiscal year, C.M. Bidwell & Associates Ltd. invested $45,000 to acquire a new share of Neurocrine Biosciences. The Central Trust Company spent approximately $45,000 during the third quarter to purchase a new investment in Neurocrine Biosciences. The price of the investment was not disclosed. The last piece of news, but certainly not the least important, is

Tags

Leave a comment

Your email address will not be published. Required fields are marked *